Maternal HIV Services
Cross-source consensus on Maternal HIV Services from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Other
Highlighted claims
- WHO validation requires antenatal care coverage of at least 95%. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
- WHO validation requires HIV testing during pregnancy coverage of at least 95%. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
- WHO validation requires antiretroviral treatment coverage of at least 95% among pregnant women with HIV. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
- Consistent access to maternal, neonatal, and HIV services across Brazil creates operational and logistical challenges. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial